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The nociceptin (NOP) receptor is a G-protein-coupled receptor whose natural ligand is the NOP/orphanin FQ (N/OFQ) peptide.
Evidence from pharmacological studies suggests that the N/OFQ system is implicated in the regulation of several addiction-related
phenomena, such as drug intake, withdrawal, and relapse. Here, to further explore the role of NOP system in addiction, we used NOP
(− /− ) rats to study the motivation for cocaine, heroin, and alcohol self-administration in the absence of N/OFQ function. Conditioned
place preference (CPP) and saccharin (0.2% w/v) self-administration were also investigated. Results showed that NOP (− /− ) rats self-
administer less cocaine (0.25, 0.125, or 0.5 mg/infusion) both under a fixed ratio 1 and a progressive ratio schedule of reinforcement
compared with wild-type (Wt) controls. Consistently, cocaine (10 mg/kg, i.p.) was able to induce CPP in Wt but not in NOP (− /− ).
When NOP (− /− ) rats were tested for heroin (20 μg/infusion) and ethanol (10% v/v) self-administration, they showed significantly lower
drug intake compared with Wt. Conversely, saccharin self-administration was not affected by NOP deletion, excluding the possibility of
nonspecific learning deficits or generalized disruption of reward mechanisms in NOP (− /− ) rats. These findings were confirmed with
pharmacological experiments using two selective NOP antagonists, SB-612111 and LY2817412. Both drugs attenuated alcohol self-
administration in Wt rats but not in NOP (− /− ) rats. In conclusion, our results demonstrate that genetic deletion of NOP receptors
confers resilience to drug abuse and support a role for NOP receptor antagonism as a potential treatment option for drug addiction.
Neuropsychopharmacology (2017) 42, 695–706; doi:10.1038/npp.2016.171; published online 21 September 2016
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INTRODUCTION
The nociceptin (NOP; or opioid-receptor-like) receptor is a
G-protein-coupled receptor whose natural ligand is the
neuropeptide NOP/orphanin FQ (N/OFQ; Meunier et al,
1995; Reinscheid et al, 1995).
Neuroanatomical and immunohistochemical studies have
shown that N/OFQ and its receptor are widely distributed in
brain areas involved in reward and motivation and have a
determinant role in shaping drug abuse-related behaviors.
High-to-moderate receptor expression has been reported in
the central nucleus of the amygdala (CeA), the bed nucleus of
stria terminalis (BNST), medial prefrontal cortex, ventral
tegmental area (VTA), lateral hypothalamus, nucleus ac-
cumbens, and some brainstem areas, including the locus
coeruleus and dorsal raphe (Ciccocioppo et al, 2000a;
Darland et al, 1998; Mollereau and Mouledous, 2000).
Consistent with this localization, evidence suggests that
the N/OFQ system is involved in the regulation of several
addiction-related phenomena, including drug intake, with-
drawal, and relapse for a variety of psychotropic agents
including opioids, psychostimulants, and ethanol
(Ciccocioppo et al, 2000a; Kallupi et al, 2014; Witkin et al,
2014; Zaveri, 2011).
Genetic association studies in humans further support the
notion of a link between the N/OFQ system and drug
addiction. For example, Huang et al. (2008) have reported a
single-nucleotide polymorphism (SNP rs6010718) in the
gene encoding the NOP receptor in alcohol-dependent
individuals. In other studies, genetic variants of the OPRL1
gene were associated with opioid dependence (Xuei et al,
2008; Briant et al, 2010). In addition, increased vulnerability
to alcohol dependence has been recently linked to DNA
hypermethylation of the promoter regions of several genes,
including the one encoding the NOP receptor suggesting
the possibility that alcohol abuse is associated with a
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repressed NOP gene transcription (Zhang et al, 2013).
Altogether, these studies confirm the important role of the
NOP system in modulating addictive behavior and also
suggest that changes in NOP receptor expression may occur
during the transition from an occasional drug intake to drug
addiction.
Preclinical data showed that intracranial administration of
N/OFQ was able to prevent the acquisition of conditioned
place preference (CPP) induced by morphine (Ciccocioppo
et al, 2000b; Sakoori and Murphy, 2008b). However, when
other aspects of opioid addiction were investigated, some
negative results were obtained. For example, N/OFQ failed to
modify the development of morphine-induced locomotor
sensitization (Ciccocioppo et al, 2000b) and did not alter
heroin self-administration in rats (Walker et al, 1998).
It was also shown that N/OFQ prevents the expression of
CPP engendered by psychostimulants such as cocaine or
methamphetamine (Kotlinska et al, 2002; Zhao et al, 2003).
Data were replicated following peripheral administration of
brain penetrant synthetic agonists (Rutten et al, 2010).
Strongest evidence for a role of NOP agonism as an
efficacious approach to treat drug addiction comes
from studies carried out in alcohol-preferring marchigian
sardinian (msP) rats, an animal line genetically selected for
high ethanol preference and excessive drinking (Ciccocioppo
et al, 2006). In these rats, NOP agonists attenuate home
cage alcohol drinking, operant alcohol self-administration,
and drug seeking elicited by stress and environmental
conditioning factors (Ciccocioppo et al, 2004; Economidou
et al, 2006a, 2008). The efficacy of NOP agonists on alcohol
intake has also been documented in post-dependent outbred
Wistar rats whereas they are not effective in non-
dependent Wistar rats, unless very high doses are used
(de Guglielmo et al, 2015a; Economidou et al, 2006a; Kuzmin
et al, 2007).
Nevertheless, the assumption that activation of NOP
receptors may have a therapeutic potential in addiction, is
incompatible with other studies that we have recently
published, in which we demonstrated that the msP rat line
showed higher expression of N/OFQ and NOP receptor
mRNA in numerous brain regions compared with their
Wistar counterparts, accompanied by significantly increased
NOP receptor binding within the CeA, BNST, VTA, and
several cortical structures (Economidou et al, 2008). These
observations are, in fact, indicative of an association between
innate upregulation of the N/OFQ-NOP system and high
ethanol preference in msP rats.
Most importantly, we have recently found that blockade
of NOP receptors by selective antagonism, attenuates
alcohol consumption, and seeking in genetically selected
alcohol-preferring rats, rising the possibility that receptor
blockade might be beneficial in alcoholism (Rorick-Kehn
et al, 2016).
Recently, using a target-selected N-ethyl-N-nitrosourea
(ENU)-driven mutagenesis, a new mutant rat line carrying a
constitutive deletion of the NOP receptor due to the
induction of a premature stop codon in the gene coding
for the ORL-1 receptor transcript has been generated
(Homberg et al, 2009). This new animal model has already
been characterized behaviorally by Rizzi et al (2011) who
found that, consistent with antidepressant properties of
NOP antagonists, NOP-receptor knock-out NOP (− /− ) rats
displayed resilience to depressive-like behaviors (Gavioli and
Calo, 2013; Holanda et al, 2016; Rizzi et al, 2011; Witkin et al,
2014). On the other hand, in agreement with the anxiolytic-
like effects of NOP agonists, NOP (− /− ) rats expressed a
mild anxious-like phenotype (Jenck et al, 2000; Rizzi et al,
2011). These findings indicate that this rat model fulfills
important criteria of face and construct validity, and can be
useful to expand our knowledge on the role of NOP receptors
in the modulation of behaviors controlled by this peptidergic
system.
Here, to better clarify the role of NOP in the modulation
of addictive related behaviors, we used this rat line to
examine the consequence of genetic deletion of the receptor
on the self-administration of some of the most commonly
abused drugs, such as cocaine, heroin, and alcohol, under
fixed and progressive ratio schedules of reinforcement.
Self-administration of the natural reinforcer saccharin
was also studied. Finally, using two chemically unrelated
selective NOP antagonists, namely LY2817412 and
SB-612111 (Rizzi et al, 2007; Toledo et al, 2014), we provided
pharmacological confirmation of our findings in NOP
receptor (− /− ) rats.
MATERIALS AND METHODS
Animals
NOP receptor (− /− ) rats were in-licenced from Genoway
(Lion, France) and were bred at the University of Camerino.
This rat line was originally generated at the Hubrecht
Institute (The Netherlands) by target-selected ENU-induced
mutagenesis on a Brown Norway background (Homberg
et al, 2009). Heterozygous mutants were then outcrossed
onto a Wistar Han to eliminate confounding effects from
other mutations that may have been induced by the ENU
mutagenesis. Biochemical characterization revealed that the
NOP receptor is completely absent in homozygous knock-
out rats, and no adaptive change in other opioid receptor
levels and distribution has occurred (Homberg et al, 2009).
Although Wt littermates for NOP (− /− ) were not
available, Wt controls (Wistar Han rats) were purchased
from Charles River (Calco, Italy) and maintained at the
University of Camerino. To attenuate potential bias linked to
this litter effect, careful attention was made to maintain the
two rat lines under identical environmental conditions
throughout the study. Nonetheless, confounding factors even
though minimal associated with lack of littermates cannot be
fully excluded.
At the beginning of the experiments, animals’ body weight
ranged between 200 and 250 g. They were housed in groups
of two in a room with artificial 12 : 12 h light/dark cycle
(lights off at 09:00 hours), constant temperature (20–22 °C)
and humidity (45–55%). All animals were handled once daily
for 5 min for 1 week before the beginning of the experiments.
During the entire period of the experimental phase, rats were
offered free access to tap water and food pellets (4RF18,
Mucedola, Settimo Milanese, Italy). Experiments were
performed during the dark phase of the light/dark cycle.
All procedures were conducted in adherence to the
‘European Community Council Directive for Care and Use
of Laboratory Animals’.
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Intravenous Surgery
For intravenous (IV) surgery, incisions were made to expose
the right jugular vein and the back between the shoulders; a
catheter made from micro-renathane tubing (I.D.= 0.020 in,
O.D.= 0.037 in; Braintree Scientific) was subcutaneously
positioned between these two points. After insertion into
the vein, the proximal end of the catheter was anchored to
the muscles underlying the vein with surgical silk sutures.
The distal end of the catheter was attached to a stainless-steel
cannula bent at a 90° angle. The cannula was inserted in a
support made by dental cement and covered with a plastic
cap. For 1 week after surgery, rats received daily injections of
0.2 ml of the antibiotic sodium cefotaxime (262 mg/ml). For
the duration of the experiments catheters were flushed daily
with 0.2–0.3 ml of heparinized saline solution. Body weights
were monitored every two days and catheter patency was
confirmed approximately every 7 days with an injection of
0.2–0.3 ml of thiopental sodium (250 mg/ml) solution.
Patency of the catheter was assumed if there was an
immediate loss of reflexes. Self-administration sessions
began 1 week after surgery.
Drugs
Cocaine hydrochloride (Johnson Matthey, Edinburgh, UK)
was dissolved in sterile physiological saline (0.9% NaCl) at a
concentration of 0.125, 0.25, and 0.5 mg/infusion. It was
given IV for the self-administration experiments. For the
CPP experiment, cocaine at the dose of 10 mg/kg was
administered intraperitoneally. Heroin was purchased by
SALARS (Como, Italy), and dissolved in sterile saline
solution (0.9% NaCl) at the concentration of 20 μg/0.1 ml
and given IV. Alcohol drinking solution 10% (v/v) was
prepared by dilution of ethanol 95 % (v/v; F.L. Carsetti s.n.c.
Camerino, Italy) in tap water. Saccharin drinking solution
0.2% (w/v) was prepared by dissolving saccharin sodium salt
hydrate 98 % (Sigma-Aldrich) in tap water. Two selective
NOP receptor antagonists, SB-612111 [(-)-cis-1-methyl-7-
[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetra-
hydro-5H-benzocyclohepten-5-ol] and LY2817412 [2′-
chloro-4′,4′-difluoro-1-{[1-(3-fluoropyridin-2-yl)-3-methyl-
1H-pyrazol-4-yl]methyl}-4′,5′-dihydrospiro[piperidine-4,7′-
thieno[2,3-C]pyran]2,3-dihydroxybutanedioate], were synth-
esized at Lilly Research Laboratories according to previously
published methods and dissolved in a formulation that
consisted of a 1 : 1 mixture of distilled water and 1M H3PO4
(Spagnolo et al, 2007; Toledo et al, 2014). The compounds
were first wet with 20% of water. The remaining portion of
water and the 1M H3PO4 solution were gradually added.
Gentle warming in a 45–60 °C water bath was used in order
to completely dissolve the compound until a clear and
homogeneous solution was achieved. It was freshly prepared
every test day and administered orally in a volume of 3 ml/kg
via gavage.
Self-Administration Apparatus
The self-administration stations consisted of operant con-
ditioning chambers (Med Associates, St Albans, VT)
enclosed in sound attenuating, ventilated environmental
cubicles. Each chamber was equipped with a drinking
reservoir (volume capacity: 0.30 ml), positioned 4 cm above
the grid floor in the center of the front panel of the chamber,
and two retractable levers (the drug-paired active lever and
the inactive control lever) located 3 cm to the right and to the
left of the drinking reservoir. Fluid delivery, count of the
number of lever presses and presentation of visual stimuli
(illumination of a cue light) were controlled by an IBM-
compatible computer. Cocaine and heroin solutions were
delivered by a plastic tube that was connected with the
catheter before the beginning of the session, whereas alcohol
and saccharin solutions were delivered in the drinking
reservoir. An infusion pump was activated by responses on
the right (active) lever and resulted in a delivery of 0.1 ml of
fluid, whereas responses on the left (inactive) lever were
recorded but did not result in any programmed
consequences.
CPP Apparatus
The CPP chambers consisted of two equally sized compart-
ments (30 ×30 × 30 cm) with distinct tactile and visual cues
(one compartment had a black floor with an equally spaced
stainless-steel stripe-like grid on the top, and white walls with
black vertical stripes, the other compartment had a white
floor and walls with horizontal black stripes), which
were separated by a guillotine door. The CPP chambers
were positioned in a dark room and two red lamps were
positioned at the adjacent angles.
Cocaine and Heroin Self-Administration under Fixed
Ratio 1 Schedule of Reinforcement
After IV catheter implantation, Wt and NOP (− /− ) rats
were left for one week in their home cages in order to recover
from surgery. Animals were then trained to self-administer
cocaine (0.125, 0.25, and 0.5 mg/0.1 ml) or heroin (20 μg/
0.1 ml) under a fixed ratio 1 (FR1) with 20 s time-out (TO)
schedule of reinforcement, in which each response at the
drug-paired active lever resulted in the IV delivery of 0.1 ml
of fluid, whereas responses at the inactive lever resulted in no
fluid delivery (Kallupi et al, 2010). Rats received 2 h daily
sessions for 13–14 consecutive days.
Cocaine and Heroin Self-Administration under
Progressive Ratio Schedule of Reinforcement
Animals were first trained to FR1 self-administration until
stable baseline of responding was achieved. Rats were then
tested under a progressive ratio (PR) schedule of reinforce-
ment to measure the breakpoint (BP), defined as the last
ratio completed by the animal for the acquisition of the next
reward. The number of lever responses or the ratio required
to receive one dose of cocaine was increased as follows: 5,11,
18, 26, 35, 45, 56, 68, 82, 98, 116, 136, 158, 182, 208, 236, 268,
304. Additional groups of rats were employed for heroin self-
administration. As for cocaine, these animals were first
trained under an FR1 schedule of reinforcement and then
were switched to a PR schedule where the response
requirements necessary to receive a single reward increased
according to the following progression: 1, 2, 4, 6, 9, 12, 15, 20,
25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, and so on
(de Guglielmo et al, 2015b; Richardson and Roberts, 1996).
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The sessions were terminated when 460 min had elapsed
since the last reinforced response. The PR is an operant
schedule that allows measuring the maximum amount of
work an animal is willing to carry out to obtain the reward,
reflecting its motivation for it.
Acquisition of Alcohol and Saccharin
Self-Administration
Wt and NOP (–/–) rats were trained to self-administer
ethanol (10% v/v) or saccharin (0.2% w/v) solution in 30 min
daily sessions under an FR1 schedule of reinforcement, in
which each response at the active lever resulted in the
delivery of 0.1 ml of fluid, whereas responses at the inactive
lever resulted in no fluid delivery. Each reward delivery
was associated with 5 s time-out (TO 5 s) signaled by
illumination of the cue light. Alcohol or saccharin self-
administration training continued until stable baselines of
responding were established. To facilitate acquisition of lever
pressing for alcohol, a classical saccharin fading procedure
was used during which ethanol concentration was progres-
sively increased to reach (10% v/v) and saccharin progres-
sively removed from the fluid. Water and food were freely
available in the home cages during the entire experimental
period.
Alcohol and Saccharin Self-Administration under PR
After the completion of alcohol and saccharin-acquisition
phase, rats were tested under a PR schedule of reinforcement
to measure the BP for alcohol and saccharin. For this
purpose, animals previously trained to FR1 (10% v/v) alcohol
or saccharin (0.2% w/v) solution self-administration, were
then tested under PR contingency, in which the response
requirement to receive one dose of ethanol or saccharin was
increased as follows: for each of the first four ethanol or
saccharin deliveries, the ratio was increased by 1; for the next
four deliveries the ratio was increased by 2; for all the
following deliveries the ratio was increased by 4. Each
reinforced response resulted in a 1 s illumination of the cue
light, whereas sessions were terminated when 430 min had
elapsed since the last reinforced response (Economidou et al,
2006b).
Effect of the NOP Antagonists SB-612111 and
LY2817412 on Ethanol Self-Administration in NOP
( − / − ) and Wt Rats
To confirm findings generated in NOP (− /− ) rats, we
administered two chemically unrelated highly selective NOP
antagonists, SB-612111 and LY2817412 to NOP (− /− ) and
Wt rats and the effect of receptor blockade on alcohol self-
administration was tested. Receptor-binding affinity (Ki) and
functional antagonist potency of SB-612111 and LY2817412
(Table 1) were determined in Chinese Hamster Ovary cells
expressing the NOP receptor according to previously
published methods (Statnick et al, 2016).
After the acquisition of a stable baseline of ethanol
self-administration, Wt (n= 7) and NOP (− /− ) (n= 8) rats
were treated orally with SB-612111 (0.0, 3.0, and 30.0 mg/kg),
according to a within-subject Latin square design, in which
each animal received in a counterbalanced order all drug
Table 1 NOP Antagonist in vitro Receptor-Binding Affinity (Ki) and Functional Antagonist Potency (Kb)
Compound Structure Binding affinity (Ki, nM±SEM) Antagonist potency (Kb, nM±SEM)
LY2817412 0.176± 0.05 0.273± 0.12
SB612111 0.253± 0.15 0.258± 0.13
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doses. Drug doses were chosen based on our previous
experience with this compound and published data (Rizzi
et al, 2007; Toledo et al, 2014).
Before the beginning of the treatment, rats were acclimated
to gavage administration procedures for three consecutive
days, during which they received distilled water to familiarize
them with the injection procedure, after which the experi-
ment began. Drugs or vehicle were administered 60 min
before the beginning of the self-administration session. Tests
were performed every 3 days. The day after the experiment,
animals were left undisturbed and the subsequent day a new
baseline of alcohol self-administration was re-established.
After having completed the experiment with the
SB-612111, a new baseline for alcohol self-administration
was re-established for 1 week and then the same procedure
was repeated to test LY2817412 (0.0, 1.0, and 10.0 mg/kg).
A 10 mg/kg dose of LY2817412 produced 55% receptor
occupancy of NOP receptors in the brain 24 h after
administration (Toledo et al, 2014).
Cocaine-Induced CPP
On day 0 (pretest), rats freely explored the two compart-
ments for 15 min, and the time spent in each compartment
during the exploratory period was measured. Rats that spent
60–70% (4630 s) of the total time (15 min) in one side were
excluded from the experiment. We used an unbiased-like
protocol and we assigned the drug-paired compartment
randomly to the rats. On days 1–3 (conditioning), rats were
given alternating injections of cocaine (10 mg/kg, i.p.) or
saline (1 ml/kg, i.p.) twice daily (0900 hours to 1900 hours)
and confined to one compartment for 30 min for 3
consecutive days. On day 4 (test day), rats were allowed to
explore the two compartments freely for 15 min and the time
spent in each compartment during the exploratory period
was measured.
Statistical Analysis
For data evaluation, the analysis of variance (ANOVA) was
used followed by Newman–Keuls post hoc tests. In detail,
number of rewards in Wt and NOP (− /− ) rats during the
acquisition phase of cocaine, heroin, alcohol, and saccharin
were analyzed by means of a two-way ANOVA with one
factor between (rat line) and one factor within (days/
sessions). For the CPP test, strain was considered as the
between factor, whereas treatment (cocaine vs saline) was
considered as the within factor. For the PR test, an unpaired
Student’s t-test was used to analyze the rewards acquired by
wild-type compared with the NOP (− /− ) rats. The effect of
SB-612111 and LY2817412 was evaluated by a two-way
ANOVA with one factor between (rat line) and one factor
within (treatment) followed by Newman–Keuls tests. Statis-
tical significance was set at Po0.05.
RESULTS
NOP ( − / − ) Rats Self-Administer Less Cocaine
Compared with Wt Counterparts and have a Reduced
Motivation for the Drug
Wt (n = 9) and NOP (–/–) rats (n = 7) were trained to self-
administer cocaine (0.25 mg/0.1 ml, IV) for 13 consecutive
days in 2 h daily sessions under the FR1 schedule of
reinforcement. ANOVA showed a significant effect of strain
(F(1,14)= 8.46; Po0.05), significant effect of session
(F(12,168)= 14.77; Po0.0001) and a significant interaction
‘strain × session’ (F(12,168)= 3.003; Po0.001). NOP (− /− )
rats self-administered significantly less cocaine compared
with Wt rats, as revealed by the post hoc Newman–Keuls
analysis in days 4, 5 (Po0.01), 6 (Po0.05) and 7–13
(Po0.001; Figure 1a). After completion of cocaine acquisi-
tion under FR1, Wt and NOP (− /− ) rats were switched to a
PR schedule of reinforcement. Data analysis by means of
unpaired Student’s t-test showed a reduced number of
cocaine reinforcements t(14)= 3.370, Po0.01) in the NOP
(− /− ) rats compared with the Wt (Figure 1b).
Reduced Motivation for Cocaine in NOP ( − / − ) Rats
does not Depend upon Altered Drug Sensitivity
To determine whether attenuated cocaine self-administration
depends upon a different sensitivity to its rewarding effect,
NOP (− /− ) and Wt were tested for multiple drug
concentrations. Wt (n= 7) and NOP (− /− ) (n= 7) rats
were trained to self-administer cocaine solution (0.25 mg/
Wt NOP (-/-)
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Figure 1 (a) Acquisition pattern (13 days) of cocaine (0.25 mg/infusion) self-administration in NOP (− /− ; n= 7) indicated with black circles, and in wild-
type (Wt) rats (n= 9) in white circles, under an FR1 schedule of reinforcement. Results are expressed as mean± SEM of number of rewards acquired by
animals. (b) Illustrates the mean± SEM of number of cocaine infusions (rewards) and mean± SEM of the breakpoint (BP) achieved by NOP (− /− ) in black
column and Wt rats in white column during cocaine self-administration under a progressive ratio schedule of reinforcement, significant difference between Wt
and NOP (− /− ). ***Po0.0001; **Po0.01; *Po0.05.
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0.1 ml, IV) for 13 consecutive days in 2 h daily sessions under
the FR1 schedule of reinforcement. Once stable baseline of
cocaine self-administration was reached, animals were
switched to a PR schedule of reinforcement. At this point,
half of the rats were switched to the lowest concentration of
cocaine (0.125 mg/0.1 ml, IV) and half to the highest
concentration (0.5 mg/0.1 ml, IV). Sessions under FR1
contingency continued for an additional 13 consecutive
days, subsequently the PR performances were recorded.
The procedure was repeated by switching the rats from the
lowest to the highest dose and vice versa so that all rats
received all cocaine concentrations (Figure 2). A two-way
ANOVA with ‘strain’ as a between factor and ‘session’ as a
within factor was performed to separately analyze the
amount of cocaine acquired (expressed in mg) at the three
concentrations of cocaine tested. For the lowest cocaine
concentration (0.125 mg/0.1 ml, IV), statistical analysis
revealed a significant effect of strain (F(1,12)= 10.75;
Po0.01), session (F (12,144)= 7.55; Po0.001) and ‘strain ×
session’ interaction (F(12,144)= 2.77; Po0.01; Figure 2a).
Similar results were obtained for the intermediate concen-
tration (0.25 mg/0.1 ml, IV) where the two-way ANOVA
revealed an effect of strain (F(1,12)= 11.43; Po0.01), session
(F(12,144)= 6.33; Po0.001) and ‘strain × session’ interaction
(F(12,144)= 4.326; Po0.05; Figure 2b). When self-
administration data from the highest dose (0.5 mg/0.1 ml,
IV) were analyzed, we found a significant effect of strain
(F(1,11)= 67.17; Po0.001) and session (F(12,132)= 4.29;
Po0.001) but the interaction term was not significant
(F(12,132)= 1.40; P=NS; Figure 2c). During this latter
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Figure 2 Self-administration pattern registered at different doses (a) 0.125, (b) 0.25, and (c) 0.5 mg/infusion of cocaine in Wt rats (n= 7) shown in white
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phase, one Wt rat lost the catheter and it was excluded from
the statistical analysis.
In a subsequent analysis, when ANOVA was used to
evaluate the difference between Wt and NOP (− /− ) rats in
average cocaine intake at different concentrations for the
entire 13 session period, a significant effect of strain
(F(1,11)= 86.13; Po0.001) and cocaine dose (F(2,
22)= 18.49; Po0.001) were confirmed, but no effect of the
interaction ‘strain × cocaine concentration’ was found
(F(2,22)= 2.65; Po0.05). The post hoc Newman–Keuls
analysis confirmed that, compared with Wt rats, NOP
(− /− ) rats self-administered significantly less cocaine at all
concentrations tested (Po0.001; Figure 2d).
When PR response at different concentrations of cocaine
was evaluated, results analyzed by two-way ANOVA with
‘strain’ as a between factor and ‘cocaine concentration’ as a
within factor showed a significant effect of strain
(F(1,11)= 13.43; Po0.01), a trend to an effect of concentra-
tions (F(2, 22)= 3.03; P= 0.06) and no ‘strain × cocaine
concentration’ interaction (F(2,22)= 0.34; P= 0.7). As shown
in Figure 2e, NOP (− /− ) showed a marked reduction in the
number of cocaine rewards achieved (Po0.01).
Cocaine Induces CPP in the Wt but not in NOP ( − / − )
Rats
Wt (n= 10) and NOP (− /− ) rats (n= 10) previously
conditioned for cocaine were tested for 15 min in the CPP
test. The CPP effect was determined by analyzing the time
spent in the cocaine vs saline-paired compartment in the test
day. ANOVA showed a significant difference of treatment
(F(1,18)= 4.98; Po0.05), and a significant interaction
‘strain × treatment’ (F(1,18)= 4.44; Po0.05). Post hoc
Newman–Keuls analysis revealed that the Wt rats spent
more time in the cocaine-paired compartment compared
with the saline-paired one (Po0.05), whereas no difference
between the time spent in cocaine or saline-paired compart-
ment was observed in the NOP (− /− ) counterpart
(Figure 2f).
NOP ( − / − ) Rats Self-Administer Less Heroin
Compared with Wt Counterparts and have a Reduced
Motivation for the Opioid
Wt (n= 11) and NOP (− /− ) rats (n=10) were trained to
self-administer heroin (20 μg/0.1 ml, IV) for 14 consecutive
days in 2 h daily sessions under the FR1 schedule of
reinforcement until baseline was reached. ANOVA revealed
a significant effect of strain (F(1,19)= 21; Po0.001), number
of sessions (F(13, 247)= 21.9; Po0.0001), and a significant
‘strain × session’ interaction (F(13, 247)= 2.9; Po0.001).
NOP (− /− ) rats self-administered significantly less heroin
solution compared with the Wt rats and Newman–Keuls post
hoc analysis showed a significant difference in sessions 1 and
4 (Po0.05), and a highly significant difference for the rest of
the sessions (Po0.001; Figure 3a).
Once stable baseline of responding under FR1 was
established, Wt and NOP (− /− ) rats were tested in a PR
schedule of reinforcement. Statistical analysis by means of
unpaired Student’s t-test showed a significant reduction in
the PR responding for heroin t(19)= 2.526, Po0.05) in NOP
(− /− ) rats compared with the Wt rats (Figure 3d).
Acquisition of Alcohol Self-Administration in NOP
( − / − ) vs Wt Rats
Wt (n= 8) and NOP (–/–) rats (n=7) were trained to
self-administer 10% (v/v) ethanol in 30 min daily
sessions under the FR1 schedule of reinforcement. ANOVA
revealed a significant effect of strain (F(1,13)= 20.72;
Po0.001) but no effect of session (F(13,169)= 2.6;
P=NS) or ‘strain × sessions’ interaction (F(13,169)= 2.79;
P=NS; Figure 3b), reflecting the fact that throughout the test
period, NOP (− /− ) rats self-administered less alcohol
than Wt.
After acquisition of stable baseline alcohol self-
administration under FR1, Wt and NOP (− /− ) rats were
tested in a PR schedule of reinforcement. Unpaired
Student’s t-test revealed significantly fewer number of
alcohol rewards t(12)= 4.133, Po0.01) in the NOP (− /− )
rats compared with Wt counterparts (Figure 3e). In the PR
experiment, one Wt rat was excluded because of health
issues, consequently this test was carried out with 7 Wt and
7 NOP (− /− ).
NOP ( − / − ) and Wt Rats do not Differ in Saccharin Self-
Administration
Wt (n= 9) and NOP (–/–) rats (n=9) were trained to self-
administer (0.2% w/v) saccharin solution under an FR1
schedule of reinforcement in 30 min daily sessions for
13 days. ANOVA did not show any significant difference
in saccharin self-administration between lines (F
(1,16)= 1.29; P=NS). Lever pressing for saccharin progres-
sively increased over days leading to a significant effect of
time (F(12,192)= 52.84; Po0.0001). ANOVA failed to detect
any significant ‘strain × session’ interaction (F(12,192)= 0.79;
P=NS; Figure 3c).
After completion of FR1 saccharin self-administration, Wt
and NOP (− /− ) rats were tested under a PR schedule of
reinforcement to measure the motivation for saccharin.
Unpaired Student’s t-test showed no statistically significant
difference t(16)= 0.93, P=NS) between NOP (− /− ) and
Wt rats (Figure 3f).
NOP Antagonism Reduces Alcohol Self-Administration
in Wt, but not in NOP ( − / − ) Rats
Analysis of the number of rewards acquired, revealed a
significant effect of line (F(1,13)= 20.5; Po0.001),
treatment (F(2,26)= 5,42; Po0.05), and ‘strain × treatment’
interaction (F(2,26)= 4.27; Po0.05). Post hoc Newman–
Keuls analysis showed that Wt self-administered significantly
higher amounts of ethanol compared with NOP (− /− )
rats (Po0.001). To test the effects of NOP receptor
blockade on alcohol self-administration, we employed
two potent small-molecule antagonists (Table 1). SB-612111,
at both doses tested (3 and 30 mg/kg) significantly reduced
the number of alcohol rewards in the Wt rats (Po0.01), but
did not affect alcohol intake in the NOP (− /− ) rats
(Figure 4a).
The effect observed with SB-612111 was then confirmed
using LY2817412. Indeed, overall two-way ANOVA
revealed a significant line difference (F(1,13)= 13.3;
Po0.01) and a significant ‘strain × treatment’ interaction (F
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(2,26)= 3.78; Po0.05), but no main effect of treatment
(F(2,26)= 2.19; P=NS; Figure 4b). Post hoc analysis
confirmed that Wt rats self-administered significantly
higher levels of alcohol compared with NOP (− /− ) rats
(Po0.01). Moreover, results indicated that LY2817412
significantly attenuated alcohol consumption in Wt rats (at
the 10 mg/kg dose), but not in NOP (− /− ) rats at any dose
tested (Figure 4b).
DISCUSSION
The main finding of the present study was that NOP (− /− )
rats showed reduced propensity to self-administer cocaine,
heroin, and alcohol, compared with outbred controls. These
drugs have distinct psychoactive effects and different
mechanisms of action, nevertheless, their intake was
significantly blunted following NOP receptor deletion,
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Figure 3 (a) Acquisition pattern (14 days) of heroin self-administration in NOP (− /− ; n= 10) in black circles and in Wt rats (n= 11) in white circles under
an FR1 schedule of reinforcement. Results are expressed as mean± SEM of numbers of rewards acquired by rats. Significant difference between rat lines.
***Po0.0001; *Po0.05. (b) Acquisition pattern (15 days) of alcohol self-administration in NOP (− /− ; n= 7) and in Wt rats (n= 8) under an FR1 schedule
of reinforcement. Results are expressed as mean± SEM of numbers of rewards (0.1 ml of 10% ethanol) acquired by animals. Significant difference between rat
lines. ***Po0.0001. (c) Acquisition pattern (14 days) of saccharin (0.2%) self-administration in NOP (− /− ; n= 9) and in Wt rats (n= 9) under a FR1
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administration under a progressive ratio schedule of reinforcement.
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suggesting that this receptor has a remarkable role in
the regulation of drug reward. We also tested NOP (− /− )
rats for saccharin self-administration; in this case, we did not
find differences compared with Wt counterparts, indicating
that deletion of NOP receptors does not affect the motivation
for natural reinforcers. The lack of effect on saccharin self-
administration rules out the possibility that the altered
response toward drugs of abuse in NOP (− /− ) rats was
dependent upon reduced activation of brain reward circuitry,
nonspecific locomotor deficits, or learning impairment.
NOP ( − / − ) Rats Show Reduced Propensity to Self-
Administer Cocaine, Heroin, and Alcohol, Compared
with Outbred Controls
Theoretically, drug self-administration between NOP (− /− )
and Wt rats could differ due to differences in pharmacoki-
netic mechanisms responsible for the absorption, metabo-
lism, or excretion of the various drugs. Although direct
measurements of brain or cerebrospinal fluids levels of drugs
were not compared in NOP (− /− ) and Wt rats, it is highly
unlikely that the different intake observed is due to
pharmacokinetic factors, considering that the pathways
through which these drugs are metabolized and excreted
are different.
Alternatively, it is possible that NOP receptor deletion
shifted the reward threshold of drug self-administration. To
test this possibility, we evaluated the self-administration of
increasing concentrations of cocaine in NOP (− /− ) and Wt
controls. In rats, the standard training dose of cocaine
(0.25 mg/infusion) robustly maintained operant responding
under both FR and PR contingencies. At lower concentra-
tions (0.125 mg/infusion), cocaine-related lever pressing was
also maintained but with blunted reinforcing effects.
Conversely, at the highest concentration (0.5 mg/infusion)
tested, this psychostimulant reached its maximal reinforcing
potential. Results described in the present work align with
historically reported reinforcing effects of cocaine (Semenova
and Markou, 2003), specifically that cocaine intake and BP
measured in both Wt and NOP (− /− ) rats were lowest at
0.125 mg/infusion and highest at 0.5 mg/infusion. Most
importantly, despite the fact that direct parametric analysis
of dose difference were not carried out, we observed that,
regardless of the concentration of cocaine tested, NOP
(− /− ) rats always self-administered less drug and reached
lower BP compared with their Wt counterpart.
These data strongly suggest that differences in cocaine self-
administration were not dependent upon changes in drug
sensitivity. This interpretation cannot be directly applied to
understanding the role of NOP in the modulation of the
reinforcing effects of alcohol and heroin, for which we did
not run dose-response curves. However, considering the data
on cocaine, together with the fact that motivation for
saccharin was not altered by NOP receptor deletion, it is
unlikely that changes in reward threshold are responsible for
the reduced propensity to self-administer drugs of abuse by
NOP (− /− ) rats.
NOP Antagonists Attenuate Ethanol Drinking in Wt
Rats, but not in the NOP ( − / − ) Rats
To strengthen our observation and to provide a comple-
mentary analysis of the data obtained in NOP (− /− ) rats,
we used a pharmacological approach. In particular, we tested
the effect of two chemically unrelated highly selective NOP
antagonists, namely SB-612111 and LY2817412 on operant
alcohol self-administration (Rizzi et al, 2007; Toledo et al,
2014). Results revealed that both molecules attenuated
ethanol drinking in Wt, but not in the NOP (− /− ) line.
This finding is consistent with results obtained with NOP
KO rats indicating that pharmacological blockade of NOP
reproduces the same effects observed following genetic
deletion of the receptor. Moreover, these data provide
confirmation for a recent study showing that NOP
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antagonism attenuates the motivation for alcohol (Rorick-
Kehn et al, 2016). On the basis of current literature, there are
two main observations that need to be reconciled with our
results. First, in previous work, NOP (− /− ) mice, contrary
to NOP (− /− ) rats, were characterized by enhanced
sensitivity to the rewarding and psychoactive effects of drugs
of abuse (Marquez et al, 2008, 2013; Sakoori and Murphy,
2009), as measured by higher CPP for morphine, alcohol,
and cocaine, and a slightly enhanced locomotor sensitization
following psychostimulants (Marquez et al, 2008, 2013;
Rutten et al, 2011). Moreover, in CPP studies in rats it was
shown that pharmacological blockade or genetic deletion of
NOP facilitates the acquisition of preference for a morphine-
paired compartment (Rutten et al, 2011). In contrast, other
studies showed that behavioral sensitization to methamphe-
tamine was lower in NOP (− /− ) mice (Sakoori and
Murphy, 2008a) and most importantly, the same authors
found that ethanol drinking was lower in NOP (− /− ) mice
compared with Wt mice. This finding is in line with our
results of NOP KO animals self-administering less ethanol
compared with controls. In addition, although Wt mice
exhibited enhanced methamphetamine- and ethanol-
induced CPP after chronic administration of UFP-101, this
effect was absent in NOP (− /− ) mice. Hence, although
data in NOP (− /− ) mice are not unequivocal, this
latter work suggests that also in mice, NOP receptor deletion
may counteract the effects of chronic exposure to drugs of
abuse. Clearly, the inconsistencies among data obtained from
KO animals may be dependent on the different animal
models and behavioral procedures used. Moreover, the
heterogeneity of the dose chosen and duration of drug
exposure (chronic vs acute) could be crucial for the
experimental outcomes and makes it difficult to directly
compare results from different studies. Nevertheless, these
findings, together with data showing that pharmacological
blockade of NOP attenuates alcohol self-administration and
relapse to alcohol seeking, provide support to the possibility
that inhibition of N/OFQ transmission may have beneficial
effects on addiction (Rorick-Kehn et al, 2016).
A second set of data contrasting with our findings relates
to the inhibition of drug abuse-related behaviors following
activation of NOP receptors by agonists. For instance, it has
been shown that activation of NOP receptors by N/OFQ or
by selective synthetic agonists reduces alcohol self-adminis-
tration, attenuates opioid- and cocaine-induced CPP, and
prevents reinstatement behavior (Witkin et al, 2014; Zaveri,
2011). However, a recent study reported that NOP receptor
activation did not affect cocaine CPP, nor did it affect
reinstatement behavior elicited by cocaine priming or by
administration of the pharmacological stressor yohimbine
(Sartor et al, 2016). Most importantly, in a series of studies
carried out in our laboratories, we have found that
genetically selected msP rats, that are characterized by innate
predisposition to excessive drinking, have an elevated
expression of N/OFQ and NOP receptor transcripts in
several brain areas (Economidou et al, 2008; Hansson et al,
2006). We also observed that N/OFQ signaling is heavily
affected by chronic ethanol, as evidenced by the upregulation
of NOP receptor transcript in the CeA and BNST, and of the
N/OFQ transcript in the BNST, in rats with a history of
ethanol dependence (Aujla et al, 2013). These findings
provide a link between upregulation of the NOP system
and increased propensity to excessive drinking and possibly
transition to a later stage of addiction. This hypothesis is
additionally supported by data showing that, in msP rats,
ethanol intake was enhanced following acute administration
of NOP agonists (Economidou et al, 2006a). Conversely,
ethanol consumption was progressively decreased following
repeated NOP agonist treatment and remained low for
several days after treatment discontinuation (Ciccocioppo
et al, 2014). This effect may be consistent with the hypothesis
that NOP agonists attenuate alcohol drinking through
mechanisms involving downregulation or desensitization of
NOP receptors (Ciccocioppo et al, 2014). Indeed, multiple
groups have demonstrated rapid and robust NOP receptor
desensitization and internalization in vitro in response to
either N/OFQ or synthetic NOP agonists (Corbani et al,
2004; Dautzenberg et al, 2001; Spampinato and Baiula, 2006).
Moreover, electrophysiological studies revealed that
following administration of N/OFQ, postsynaptic NOP
receptors rapidly desensitize, whereas presynaptic receptors
continue to function normally. Hence, complex reorganiza-
tion of the activity of NOP-related neurocircuitry may also
occur and may be responsible for the effects on alcohol
(Pennock et al, 2012).
In conclusion, these results demonstrate that genetic
deletion of NOP receptors confers resilience to abused
psychoactive drugs. This effect appears to be specific as
operant behavior reinforced by natural rewards (ie, sacchar-
in) is not altered in NOP (− /− ). Pharmacological
blockade of NOP receptors by selective antagonists
specifically attenuated the motivation for alcohol in Wt but
not in NOP (− /− ) rats. A novel NOP antagonist with a safe
pharmacological profile is currently under investigation for
depression in humans (Post et al, 2016). Substance use
disorders may possibly represent an additional clinical
indication for this compound.
The present work sheds new light on the role of
the N/OFQ-NOP system in addiction and prompts
a new intriguing hypothesis supporting a role for
receptor antagonism as a treatment option for drug
dependence.
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